Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-2-propen-1-one
2. 2-propen-1-one, 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-
1. 1415823-73-2
2. 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
3. Evobrutinib [inn]
4. Msc2364447c
5. M-2951
6. Msc-2364447c
7. Za45457l1k
8. M2951
9. 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one
10. 1-(4-((6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino)-methyl)-piperidin-1-yl)-propenone
11. 2-propen-1-one, 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-
12. 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-2-propen-1-one
13. 1-[4-({[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}methyl)piperidin-1-yl]prop-2-en-1-one
14. 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]-2-propen-1-one
15. M-2951; Evobrutinib
16. Evobrutinib [who-dd]
17. Unii-za45457l1k
18. Gtpl9752
19. Chembl4072833
20. Schembl14165673
21. Bdbm291522
22. Us9580449, Example A39
23. Bcp28995
24. Ex-a2691
25. Us9580449, Example A250
26. Nsc800892
27. S8777
28. Zinc205623965
29. Ab90800
30. Cs-6303
31. Db15170
32. Nsc-800892
33. Msc 2364447
34. Ac-35533
35. Bs-15355
36. Db-126809
37. Hy-101215
38. A16824
39. D71175
40. A902526
41. A250 [wo2012170976]
42. Q27295200
43. M-2951; M 2951; M2951; Msc-2364447c; Msc 2364447c; Msc2364447c
44. N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine
Molecular Weight | 429.5 g/mol |
---|---|
Molecular Formula | C25H27N5O2 |
XLogP3 | 4.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 7 |
Exact Mass | 429.21647512 g/mol |
Monoisotopic Mass | 429.21647512 g/mol |
Topological Polar Surface Area | 93.4 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 595 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of multiple sclerosis
ABOUT THIS PAGE
99
PharmaCompass offers a list of Evobrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Evobrutinib manufacturer or Evobrutinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Evobrutinib manufacturer or Evobrutinib supplier.
PharmaCompass also assists you with knowing the Evobrutinib API Price utilized in the formulation of products. Evobrutinib API Price is not always fixed or binding as the Evobrutinib Price is obtained through a variety of data sources. The Evobrutinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A AKOS032954004 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AKOS032954004, including repackagers and relabelers. The FDA regulates AKOS032954004 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AKOS032954004 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A AKOS032954004 supplier is an individual or a company that provides AKOS032954004 active pharmaceutical ingredient (API) or AKOS032954004 finished formulations upon request. The AKOS032954004 suppliers may include AKOS032954004 API manufacturers, exporters, distributors and traders.
AKOS032954004 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of AKOS032954004 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right AKOS032954004 GMP manufacturer or AKOS032954004 GMP API supplier for your needs.
A AKOS032954004 CoA (Certificate of Analysis) is a formal document that attests to AKOS032954004's compliance with AKOS032954004 specifications and serves as a tool for batch-level quality control.
AKOS032954004 CoA mostly includes findings from lab analyses of a specific batch. For each AKOS032954004 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
AKOS032954004 may be tested according to a variety of international standards, such as European Pharmacopoeia (AKOS032954004 EP), AKOS032954004 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AKOS032954004 USP).